The New England Journal of Medicine - A 30-year-old man
The New England Journal of Medicine - A 30-year-old man,FDA Approves Osimertinib (Tagrisso) for Advanced EGFR,Complete Pathologic Response to Pembrolizumab in a Patient,Case 34-2023: A 49-Year-Old Woman with Loss of Consciousness,Recalled TKA implant yielded low midterm survivorship, high